The Patents Term – Presumed Valid By
Law – Extends to 2035
HICKSVILLE, NY -- March 11, 2024 -- InvestorsHub NewsWire -- Can
B Corp., a Florida corporation (OTCQB: CANB)
("Can B"), a health and wellness company specializing in
developing, producing and selling hemp-derived cannabinoid
products, is pleased to announce that it has secured ownership and
control of two cannabis patents that were valued at $122 million,
applying a 90% discount and assuming a revenue stream through
August 2034, and further based on only CBD claims and only in the
U.S. It is believed that if the global THC and CBD markets were
added to the valuation, then the value of the patents is
potentially up to $750 million.
The two composition and use patents covering cannabis extracts
and methods of preparing the same were acquired through Can B's 67%
owned subsidiary, Nascent Pharma, LLC, and are: (1) US 9,730,911 B2
(granted August 15, 2017) and (2) US 10,555,928 B2 (granted
February 11, 2020). These patents were previously awarded to United
Cannabis Corporation and recently assigned to Can B by a court
procedure.
The patents were valued at $122 million in December 2020 by an
independent third-party valuation team, which used a 90% discount
rate due to the emerging nature of the industry. The valuation of
the patents included only CBD claims and only in the U.S. Since the
date of the valuation, the patents have become effective in Canada,
Australia, New Zealand, Israel, and Brazil and have received
additional divisional patents in the U.S. The priority date for the
patents stems back to October 2013 and have pending status in the
European Union, India, China, Eurasia, South Korea, Mexico, Japan,
and Colombia.
Of significance, the patents survived an earlier invalidity
challenge in Federal Court. The defendants claim that the patent
formulation was a naturally occurring substance (which is not
patentable). The court ruled that it was not, thereby denying the
objection.
The patents relate to the extraction of pharmaceutically active
components from plant materials, and more particularly to the
preparation of a botanical drug substance for incorporation into a
medicament and for use in pharmaceutical formulations, in
particular comprising cannabinoids obtained from cannabis.
The patents include both a composition of matter patent and a
method of use patent. The composition of matter patent covers
liquid formulations of cannabis where the present cannabinoids are
more than 95% CBD, THC, CBN, CBDa, THCa, or several combinations
thereof. This patent covers beverages, tinctures, vape pen liquids
and liquid filled capsules. This constitutes a considerable portion
of the hemp and cannabis industry, potentially up to 50%.
The method of use patent uses some of the composition of matter
combinations to potentially manage many debilitating conditions.
These include cancer, IBS, chronic pain, PTSD, anxiety, sleep
disorders and opioid dependencies.
Marco Alfonsi, Can B's Chief Executive Officer, stated, "We are
thrilled to be the proud new owners of these extremely important
and potentially very valuable cannabis patents. While cannabis
stocks have been in a bear market for the past few years, there is
no doubt that the industry has witnessed robust growth and has
become more and more acceptable, legal and mainstream, despite
still being considered a Schedule I drug under the Controlled
Substances Act. We believe there is a strong opportunity to
monetize these patents as they represent important innovations in
this industry. We look forward to updating shareholders and the
public with our plans going forward."
About Can B Corp.
Can B is a health & wellness company providing quality hemp
derived cannabinoid products, including under its own brands of
Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil. Can B utilizes
multi-channel distribution to reach consumers, including medical
facilities, doctor offices, retailers, online and direct. Can B's
Duramed medical device division operates out of its New York office
provides durable medical devices in the "No-Fault" insurance space.
Can B operates its hemp operating division in its Colorado
facilities. Nascent Pharma is Can B's newest operation in the
patent and intellectual property arena. To learn more about Can B
and our comprehensive line of high quality products, please
visit: Canbiola.com and www.CanBCorp.com;
follow Can B on Instagram
@canbcorp and Facebook
@ Can B Corp, Twitter
@CanBCorp, YouTube
@canbiola9412, or visit one of the retail outlets that
carry Can B products.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed
in this release contain forward-looking statements. The words
"anticipate," "believe," "estimate," "may," "intend," "expect," and
similar expressions identify such forward-looking statements.
Expected, actual results, performance, or achievements could differ
materially from those contemplated, expressed, or implied by the
forward-looking statements contained herein. Forward-looking
statements are subject to a number of risks and uncertainties,
including but not limited to, risks and uncertainties associated
with, among other things, the ultimate value of the patents
described above, the ability to monetize such patents, the
enforceability of the patents, the impact of economic, competitive,
and other factors affecting our operations, markets, products, and
performance. The matters discussed herein should not be construed
in any way, shape or manner of our future financial condition
operating results or stock price. Except as required by law, we
undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of latest
information, future events or otherwise, after the date on which
the statements are made or to reflect the occurrence of
unanticipated events.
Investors and Media:
IR@canbiola.com
(917) 658-7878
CAN B (QB) (USOTC:CANB)
過去 株価チャート
から 11 2024 まで 12 2024
CAN B (QB) (USOTC:CANB)
過去 株価チャート
から 12 2023 まで 12 2024
